Zepbound is FDA-approved for chronic weight management in eligible adults and for certain adults with obesity and obstructive sleep apnea
LY3437943 is the clinical research designation for Retatrutide, a triple GLP-1, GIP and glucagon receptor agonist developed by Eli Lilly
Table 3 highlights various carrier systems including liposomes, SLNs, NLCs, niosomes, nanoemulsions, and Ethosomes alongside their key actives, entrapment efficiency, particle sizes, experimental models, therapeutic advantages, and limitations
For best results, your doctor may recommend a series of 3 to 4 sessions, spaced 2 to 4 weeks apart
To manage this, your surgeon will provide compression garments
During recovery, you can resume light activities as soon as you feel up to it